Medical Students’ DNA – and Psychology – on Display in Classroom
By Jessica Cussins
| 10. 31. 2012
In a recent CBS News video segment, Eric E. Schadt, chair of the Department of Genetics and Genomic Sciences at Mount Sinai School of Medicine, enthusiastically discussed the benefits of whole-genome sequencing. When asked about the technology’s potential down sides, he answered:
The social implications, what sorts of policy we should be thinking about, those are the discussions we should be having right now, about how to leverage this information in ways that are benefitting humankind, not biasing the type of population through unnatural selection of traits.
Given this view, one would imagine that Schadt’s department is deeply engaged with these discussions. In at least one way, it is. He explained that the school is addressing the social and ethical complexities of whole-genome sequencing by offering a first-of-its-kind course in which students analyze entire genomes (either their own or an anonymous sample) and then take part in a research study on the effects of getting this information.
Put another way, the school is hoping to determine the ethics of a new technology they’ve adopted by performing it on their...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
